The Diagnostic Pitfall: How a Common Immunoassay Can Mislead Adrenal Pathology
A critical study in Clinical Endocrinology reveals a significant diagnostic challenge in the subtyping of primary aldosteronism, a condition with profound implications for cardiovascular and endocrine pathology. Researchers compared aldosterone measurements from adrenal vein sampling (AVS) using two commercial immunoassays against the gold standard of liquid chromatography-tandem mass spectrometry (LC-MS/MS). They found that the Liaison chemiluminescence immunoassay produced a high rate of apparent bilateral aldosterone suppression (ABAS)—an artefact that can incorrectly suggest both adrenal glands are inactive—in 14.5% of procedures, compared to just 0.9% with mass spectrometry. This assay-specific inaccuracy complicates the crucial diagnostic task of distinguishing unilateral from bilateral disease, directly impacting surgical decision-making for patients with adrenal tumors and hypertension.
Study Significance: For pathologists and clinical laboratories, this finding underscores the non-interchangeable nature of diagnostic assays and the potential for specific immunoassay platforms to generate misleading biomarker data that mimics a pathological state. It reinforces the necessity of rigorous laboratory quality control and, in complex endocrine diagnostics, the consideration of mass spectrometry for critical tumor subtyping to ensure diagnostic accuracy and appropriate patient management.
Source →Stay curious. Stay informed — with Science Briefing.
This is a one time Briefing, Upgrade to continue.
Upgrade and get 50% Off — Coupon: ERWMCWYU
